China Revises Medical Device Advertising Regulations: 5 Key Takeaways for Foreign Manufacturers

The National Medical Products Administration (NMPA) and State Administration for Market Regulation (SAMR) jointly released revised Medical Device Advertising Management Measures (医疗器械广告管理办法, yīliáo qìxiè guǎnggào guǎnlǐ bànfǎ) in late 2024, with a total of 28 provisions taking effect on March 1, 2025. These updates replace the 2019 version and introduce stricter content review standards, expanded prohibited statements, and higher penalties for non-compliance, affecting all foreign medical device manufacturers marketing in China.

The new rules tighten pre-approval requirements, broaden what counts as a prohibited claim, and raise maximum fines from 100,000 RMB (about 14,000 USD) under the old framework to 1,000,000 RMB (about 140,000 USD) for serious violations. Foreign companies selling devices in China through a 外商独资企业 (wholly foreign-owned enterprise, WFOE, wàishāng dúzī qǐyè) or via a Chinese distributor must now reassess their advertising and promotional materials to avoid regulatory risk.

Stricter Pre-Approval Requirements for Advertising Content

Under the revised measures, all medical device advertisements must obtain pre-approval from the provincial-level Market Supervision Administration (市场监督管理局, shìchǎng jiāndū guǎnlǐ jú) before publication. The review process now explicitly covers digital channels — including social media posts, search engine ads, and influencer endorsements — which previously operated in a regulatory gray zone. The application must include the device registration certificate, a sample of the proposed advertisement, and a compliance self-declaration.

The review timeline remains 20 working days from the date of complete submission, with a possible extension of 10 working days if the authority requests additional materials. In 2024, SAMR reported processing 58,734 medical device advertising applications nationwide, rejecting 12.3% on first submission due to non-compliant claims — up from 8.1% in 2022, reflecting the tightening enforcement trend.

Expanded List of Prohibited Claims and Comparative Statements

The 2025 revision explicitly prohibits nine new categories of statements that were not previously banned in advertising regulations. These include: (1) claims of “absolute safety” or “zero side effects”; (2) statements guaranteeing cure rates or efficacy timelines (e.g., “cures within 7 days”); (3) comparisons with competitor products unless based on publicly available, peer-reviewed clinical data; (4) use of “most,” “best,” “first” or similar superlatives without regulatory backing; (5) endorsements by unlicensed healthcare professionals or patients without documented real-world consent; (6) suggestions that a device can replace professional medical diagnosis or treatment; (7) use of government or NGO logos to imply official endorsement; (8) statements targeting minors directly without parental warning; and (9) claims referencing traditional Chinese medicine (中医, zhōngyī) unless the device is specifically registered under TCM device classification.

Foreign manufacturers should note that comparative claims are now subject to the strictest scrutiny. The revised measures require that any comparative statement must cite the exact clinical study, publication, and data source, and the competitor product’s name must be anonymized unless explicit permission is obtained. Violations of these content rules can result in fines of 300,000 to 1,000,000 RMB for the advertiser, plus a publishing ban of up to 6 months for repeat offenders.

Impact on Digital and Social Media Campaigns

The inclusion of digital channels means that retargeting ads, WeChat mini-program banners, and KOL (Key Opinion Leader) posts now require the same pre-approval as a billboard or TV commercial. A leading orthopedics device company was fined 850,000 RMB in January 2025 — just before the new rules took effect — for a WeChat campaign that used patient testimonials without documented consent. The new measures make such practices explicitly illegal, with fines starting at 200,000 RMB for first-time digital-only violations.

New Penalty Tiers and Enforcement Mechanisms

The revised measures establish four penalty tiers based on violation severity, replacing the previous single-tier fine system. Tier 1 covers minor procedural errors (e.g., missing expiry dates in the ad footer) with a warning and a fine of up to 50,000 RMB. Tier 2 applies to content violations (prohibited claims without aggravating factors) with fines of 100,000 to 300,000 RMB. Tier 3 covers serious content violations (e.g., false efficacy claims, misleading comparative statements) with fines of 300,000 to 700,000 RMB and mandatory ad withdrawal. Tier 4 covers deliberate fraud or repeated violations, with fines of 700,000 to 1,000,000 RMB, a publishing ban of up to 12 months, and referral for criminal investigation if patient harm occurred.

Enforcement is now handled jointly by SAMR and NMPA at the provincial level, with a new cross-departmental task force that conducts quarterly inspections of online advertising platforms. In 2024, 1,432 medical device advertising violations were penalized nationwide, with total fines exceeding 47 million RMB — a 36% increase over 2023 total fines. SAMR has stated that enforcement frequency will increase by 40% in the second half of 2025.

Special Requirements for Imported Medical Devices

Foreign medical device manufacturers that market in China through a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) or a 合资企业 (joint venture, hézī qǐyè) must now appoint a legal representative for advertising compliance (广告合规法律代表, guǎnggào hégūi fǎlǜ dàibiǎo) who is physically based in China. This person — typically the WFOE’s general manager or regulatory affairs head — bears personal liability for all advertising materials published in China. The representative must be named in the advertising pre-approval application and must sign a compliance declaration for each ad submission.

Additionally, all advertising materials in Chinese must include the device’s NMPA registration number (医疗器械注册证号, yīliáo qìxiè zhùcè zhèng hào) in a visible font size, and the full text of any disclaimer — such as “this device should be used under physician supervision” — must match the language in the approved device registration certificate. Foreign-language advertisements (English-language trade publications sent into China) remain subject to the same rules if they target Chinese healthcare professionals, but enforcement in practice focuses on Chinese-language materials published on domestic platforms.

What Foreign Executives Should Do Before Q3 2025

With enforcement ramping up by 40% in the second half of 2025, early action is critical. The single most important step is to conduct a full audit of all existing advertising materials — including any brochures, website copy, social media posts, and distributor-provided content that mention your devices. Second, appoint your China-based advertising compliance representative now and ensure they have a direct reporting line to your global regulatory team. Third, revise your distributor agreements to include explicit advertising compliance clauses that assign liability for violations to the party that created the material, with indemnification language favoring your WFOE.

The revised measures also grant a 6-month grace period for existing advertisements that were approved under the 2019 rules — these ads can continue running until September 1, 2025, without re-approval, provided they do not contain any of the newly prohibited claims. After that date, re-approval under the 2025 rules is mandatory.

Frequently Asked Questions on the 2025 Revisions

Q: Do the new rules apply to B2B advertising aimed at hospitals and purchasing groups?
A: Yes. The measures define a medical device advertisement as “any publication, broadcast, or digital display intended to promote a medical device to a potential user or purchaser,” which includes B2B catalogs, trade show materials, and procurement platform listings. B2B materials must also undergo pre-approval.

Q: What about internal training materials for Chinese staff and distributors?
A: Internal training materials that are not distributed outside the company or to external third parties do not require advertising pre-approval. However, if these materials are later shared with hospital staff, KOLs, or customers, they become subject to the advertising rules and must be approved.

Q: Can we still run ads that reference clinical studies published outside China?
A: Yes, but the study must be published in a peer-reviewed journal recognized by the NMPA. Studies from non-peer-reviewed sources or pre-print servers are not acceptable as supporting evidence for any claim. The ad must also include a citation to the specific journal and publication date.

NEXT STEPS

1. Audit existing advertising materials against the 2025 criteria. Use our Medical Device Advertising Compliance Checklist to identify and remove non-compliant claims before enforcement action. Focus especially on comparative statements, patient testimonials, and superlative language.
2. Appoint a China-based advertising compliance representative — typically your WFOE general manager or regulatory affairs head — and register them with the provincial SAMR office. Read our guide on WFOE Registration for Medical Device Manufacturers for details on legal representative roles.
3. Revise distributor agreements to include advertising compliance clauses with liability assignment. See our model clause template in China Distributor Agreement Best Practices for enforceable indemnification language.

— China Gateway 360 —
Remote China market entry support, built around execution.